Radalbuvir

Radalbuvir

Clinical data
Other names	GS-9669
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name 5-(3,3-Dimethylbut-1-yn-1-yl)-3-{(1R)-N-[(1s,4s)-4-hydroxy-4-({[(3S)-oxolan-3-yl]oxy}methyl)cyclohexyl]-4-methylcyclohex-3-ene-1-carboxamido}thiophene-2-carboxylic acid
CAS Number	1314795-11-3
PubChem CID	53259022
ChemSpider	31140180
UNII	273K4V0SPC
Chemical and physical data
Formula	C30H41NO6S
Molar mass	543.72 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC1=CC[C@@H](CC1)C(=O)N([C@H]2CC[C@](CC2)(O)CO[C@@H]3COCC3)c4c(sc(c4)C#CC(C)(C)C)C(=O)O
InChI InChI=1S/C30H41NO6S/c1-20-5-7-21(8-6-20)27(32)31(25-17-24(11-13-29(2,3)4)38-26(25)28(33)34)22-9-14-30(35,15-10-22)19-37-23-12-16-36-18-23/h5,17,21-23,35H,6-10,12,14-16,18-19H2,1-4H3,(H,33,34)/t21-,22-,23-,30+/m0/s1 Key:MUICUPWICXUNRS-GDCCIXDYSA-N

Radalbuvir (INN,^[1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials.^[2] It targets NS5B polymerase.^[3]

References

1. "International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. Vol. 28, no. 4. 2014. Archived from the original (PDF) on 2015-04-02.
2. "Search of: GS-9669 — List Results". ClinicalTrials.gov.
3. Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR (March 2018). "NS5B polymerase inhibitors in phase II clinical trials for HCV infection". Expert Opinion on Investigational Drugs. 27 (3): 243–250. doi:10.1080/13543784.2018.1420780. PMID 29271672. S2CID 3672885.